Table 1 Baseline characteristics of the subjects with type 2 diabetes at study enrollment
Parameter | Patients (n = 22) |
|---|---|
Age (years) | 68.0 ± 9.9 |
Male, n (%) | 15 (68) |
BMI (kg/m2) | 23.9 [22.8, 25.4] |
Duration of diabetes (years) | 18.6 ± 9.2 |
Duration of insulin therapy (years) | 9.2 ± 5.9 |
HbA1c (%) | 7.7 ± 0.6 |
Fasting plasma glucose (mg/dL) | 145.2 ± 24.3 |
Fasting serum C-peptide (ng/mL) | 1.18 [0.85, 1.58] |
eGFR (mL/min/1.73 m2) | 61.8 ± 15.0 |
Diabetic complications, n (%) | |
Retinopathy | 5 (23) |
Nephropathy | 7 (32) |
Neuropathy | 8 (36) |
Prior premixed insulin, n (%) | |
BHI30 | 12 (55) |
BIAsp30 | 10 (45) |
Oral antidiabetic agents, n (%) | |
Sulfonylurea | 1 (5) |
Metformin | 4 (18) |
αGI | 3 (14) |
DPP-4 inhibitor | 10 (46) |
SGLT-2 inhibitor | 1 (5) |
Statins, n (%) | 13 (59) |